BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22238323)

  • 1. Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin.
    Zamolodchikov D; Strickland S
    Blood; 2012 Apr; 119(14):3342-51. PubMed ID: 22238323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation.
    Henderson SJ; Stafford AR; Leslie BA; Kim PY; Vaezzadeh N; Ni R; Fredenburgh JC; Weitz JI
    Thromb Haemost; 2015 Jun; 113(6):1278-88. PubMed ID: 25789495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.
    Kim PY; Vu TT; Leslie BA; Stafford AR; Fredenburgh JC; Weitz JI
    J Biol Chem; 2014 Oct; 289(40):27494-503. PubMed ID: 25128532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin.
    Mutch NJ; Engel R; Uitte de Willige S; Philippou H; Ariëns RA
    Blood; 2010 May; 115(19):3980-8. PubMed ID: 20228273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin.
    Sakharov DV; Lijnen HR; Rijken DC
    J Biol Chem; 1996 Nov; 271(44):27912-8. PubMed ID: 8910391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
    Farrehi PM; Zhu Y; Fay WP
    J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of plasmin-mediated degradation on fibrinolysis and tissue plasminogen activator diffusion.
    Bannish BE; Paynter B; Risman RA; Shroff M; Tutwiler V
    Biophys J; 2024 Mar; 123(5):610-621. PubMed ID: 38356261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
    Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.
    Gould TJ; Vu TT; Stafford AR; Dwivedi DJ; Kim PY; Fox-Robichaud AE; Weitz JI; Liaw PC
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2544-53. PubMed ID: 26494232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
    Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
    Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
    Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
    Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
    Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of activated coagulation factor XII in overall clot stability and fibrinolysis.
    Konings J; Hoving LR; Ariëns RS; Hethershaw EL; Ninivaggi M; Hardy LJ; de Laat B; Ten Cate H; Philippou H; Govers-Riemslag JW
    Thromb Res; 2015 Aug; 136(2):474-80. PubMed ID: 26153047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin.
    Kovács A; Szabó L; Longstaff C; Tenekedjiev K; Machovich R; Kolev K
    Thromb Res; 2014 Jan; 133(1):80-7. PubMed ID: 24094605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of fibrin network by activated protein C.
    Gruber A; Mori E; del Zoppo GJ; Waxman L; Griffin JH
    Blood; 1994 May; 83(9):2541-8. PubMed ID: 8167339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.